Drawing for STADRIUS

USPTO serial 79253529

STADRIUS

Reviewed by CopyMark Law Group

Reg. 5802940Status 404
Filing date
Status date
Registration date
Jul 16, 2019
Examiner
BHANOT, KAPIL KUMAR
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with STADRIUS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 10, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Dec 10, 2022DETHDEATH OF INTERNATIONAL REGISTRATION
Sep 27, 2019GPNXNOTIFICATION PROCESSED BY IB
Sep 5, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB
Sep 5, 2019FIMPFINAL DISPOSITION PROCESSED
Aug 15, 2019GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB
Jul 16, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 30, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 10, 2019NPUBNOTICE OF PUBLICATION
Mar 19, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 18, 2019DOCKASSIGNED TO EXAMINER
Mar 15, 2019MAFRAPPLICATION FILING RECEIPT MAILED
Mar 11, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2019LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 7, 2019REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance